DMRA Damora Therapeutics, Inc. - Common Stock
NASDAQ · Ver em SEC EDGAR ↗ fechar Out 2, 2026 10-K/10-Q Ago 10, 2026
$20,65
· % da faixa de 52 semanas
· acima do mínimo
· para alta
$18,59mínima 52 sem
$34,89máxima 52 sem
Capitalização de Mercado (MRQ)
$1.27B
EPS
$3.98
seus distintivos
Intervalo 52 Semanas
$19–$35
Classificação do Analista
BUY
Preço-Alvo
$47
P/E
·
ROE
-167.0%
Margem de Lucro Líquido
-17981.1%
Sua barra de distintivos está vazia — fixe uma métrica em qualquer lugar desta página.
DMRA Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$20.65
Capitalização de Mercado (MRQ)
$1.27B
EPS
$3.98
ROE
-167.0%
Intervalo 52 Semanas
$19–$35
DMRA Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
intervalo
barras
A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.
Divisões de Ações
| Data ex | Desdobramento | Tipo |
|---|---|---|
| 30 de Agosto de 2024 | 1-for-25 | Reverso |
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
EPS$3.982021-12-31 → 2025-12-31
Fluxo de caixa livre·2021-12-31 → 2022-12-31
Margem líquida-17981.1%2021-12-31 → 2025-12-31
Avaliação e Proporções
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
| Métrica | Tendência de 5 anos | DMRA | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| P/B (MRQ) | 2.5 | · | · | · |
A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
| Métrica | Tendência de 5 anos | DMRA | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Operating Margin (Margem Operacional) | -18069.6%média 5A ≈-13005.2% | ≈-13005.2% | · | · | |
| EBITDA Margin (Margem EBITDA) | -18069.6%média 5A ≈-13005.2% | ≈-13005.2% | · | · | |
| Pretax Margin (Margem de Impostos Pré-Tributação) | -17976.8%média 5A ≈-12898.4% | ≈-12898.4% | · | · | |
| Net Profit Margin (Margem de Lucro Líquido) | -17981.1%média 5A ≈-12900.3% | ≈-12900.3% | · | · | |
| ROA | -151.2%média 5A ≈-79.1% | ≈-79.1% | · | · | |
| ROE | -167.0%média 5A ≈-105.4% | ≈-105.4% | · | · | |
| ROIC | -87.8%média 5A ≈-99.1% | ≈-99.1% | · | · |
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
| Métrica | Tendência de 5 anos | DMRA | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Índice de liquidez corrente (MRQ) | 19.7média 5A ≈12.7 | ≈12.7 | · | · | |
| Quick Ratio (Índice de Liquidez Seca) | 12.8média 5A ≈11.6 | ≈11.6 | · | · |
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
| Métrica | Tendência de 5 anos | DMRA | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Revenue YoY (Receita Ano a Ano) | 38.3%média 5A ≈121.2% | ≈121.2% | · | · | |
| Revenue CAGR 3Y (CAGR Receita 3A) | 17.4% | · | · | · |
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
| Métrica | Tendência de 5 anos | DMRA | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Asset Turnover (Giro do Ativo) | 0.0média 5A ≈0.0 | ≈0.0 | · | · |
valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
421.9%
Próximo relatório
Nov 04, 2026
| Período | Relatório | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|---|
| 30 de Junho de 2026 | Ago 3, 2026 | $-0.39 | $-0.43 | 10.2% |
| 31 de Março de 2026 | $-0.62 | $-0.40 | -56.8% | |
| 31 de Dezembro de 2025 | $2.70 | $-0.11 | 2581.6% | |
| 31 de Dezembro de 2024 | $-5.23 | $-3.03 | -72.6% | |
| 30 de Setembro de 2024 | $-3.39 | $-4.18 | 19.0% | |
| 30 de Junho de 2024 | $-4.00 | $-8.03 | 50.2% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| R&D Expense | $27M | $6M | $24M | $48M | $38M | $25M | $20M | |
| SG&A Expense | $10M | $10M | $13M | $13M | $14M | $9M | $2M | |
| Operating Expenses | $211M | $22M | $40M | $61M | $52M | $34M | $39M | |
| Operating Income | $-211M | $-22M | $-40M | $-61M | $-52M | $-34M | $39M | |
| Other Non-op | $1M | $862.0K | $2M | $-417.0K | $475.0K | $-1M | $2M | |
| Pretax Income | $-210M | $-21M | $-38M | $-62M | $-52M | $-35M | $-37M | |
| Income Tax | $50.0K | $41.0K | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-210M | $-21M | $-38M | $-62M | $-52M | $-35M | $-37M | |
| EPS (Basic) | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 | · | · | |
| EPS (Diluted) | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 | · | · | |
| Shares (Basic) | 1,363,005 | 1,157,149 | 1,062,873 | 25,409,123 | 25,261,832 | · | · | |
| Shares (Diluted) | 1,363,005 | 1,157,149 | 1,062,873 | 25,409,123 | 25,261,832 | · | · | |
| EBITDA | $-211M | $-22M | $-40M | $-61M | $-52M | $34M | · |
Balanço Patrimonial
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $258M | $14M | $21M | $33M | $63M | $164M | $11M | |
| Short-term Investments | · | · | $12M | $27M | $38M | · | · | |
| Prepaid Expense | $3M | $3M | $4M | $4M | $10M | $6M | $5M | |
| Current Assets | $260M | $17M | $37M | $64M | $110M | $169M | $56M | |
| PP&E (Net) | $36.0K | $57.0K | $78.0K | $357.0K | $203.0K | · | · | |
| PP&E (Gross) | $108.0K | $107.0K | $107.0K | $419.0K | $223.0K | · | · | |
| Accum. Depreciation | $72.0K | $50.0K | $29.0K | $62.0K | $20.0K | · | · | |
| Other Non-current Assets | $104.0K | $163.0K | $1M | $2M | $2M | $1M | · | |
| Total Assets | $261M | $17M | $38M | $73M | $122M | $172M | $57M | |
| Accounts Payable | $444.0K | $377.0K | $2M | $3M | $2M | $3M | $3M | |
| Accrued Liabilities | $2M | $820.0K | $4M | $8M | $3M | $3M | $5M | |
| Current Liabilities | $20M | $1M | $6M | $11M | $5M | $6M | $8M | |
| Capital Leases | $53.0K | $61.0K | $66.0K | $328.0K | $448.0K | $541.0K | $211.0K | |
| Other Non-current Liabilities | $81.0K | $43.0K | · | · | · | · | · | |
| Total Liabilities | $20M | $1M | $6M | $11M | $5M | $6M | $8M | |
| Paid-in Capital | $311M | $292M | $288M | $280M | $274M | $269M | $826.0K | |
| Retained Earnings | $-487M | $-278M | $-256M | $-218M | $-156M | $-104M | $-70M | |
| AOCI | $802.0K | $97.0K | $380.0K | $-244.0K | $-320.0K | $674.0K | $-2M | |
| Stockholders' Equity | $240M | $16M | $32M | $62M | $117M | $165M | $-71M | |
| Liabilities + Equity | $261M | $17M | $38M | $73M | $122M | $172M | $57M | |
| Shares Outstanding | 1,597,321 | 1,316,989 | 1,084,509 | 25,652,392 | 25,261,832 | 25,261,832 | 259,966 |
Fluxo de Caixa
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $998.0K | $3M | $5M | $6M | $4M | $982.0K | · | |
| Restructuring | · | $968.0K | $3M | · | · | · | · | |
| Operating Cash Flow | $-7M | $-19M | $-37M | $-43M | $-52M | $-38M | $-19M | |
| CapEx | · | · | · | $196.0K | $223.0K | · | · | |
| Investing Cash Flow | $-17M | $12M | $22M | $12M | $-48M | · | $-326.0K | |
| Stock Issued | · | · | $3M | $507.0K | · | · | · | |
| Net Stock Activity | · | · | $3M | $507.0K | · | · | · | |
| Financing Cash Flow | $267M | · | $3M | $507.0K | · | $187M | · | |
| Taxes Paid | $5.0K | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | $-43M | $-53M | · | · |
Lucratividade
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18069.6% | -2637.4% | -2362.6% | -8477.4% | -33478.8% | · | · | |
| Net Margin | -17981.1% | -2540.2% | -2270.5% | -8535.2% | -33174.4% | · | · | |
| Pretax Margin | -17976.8% | -2535.3% | -2270.5% | -8535.2% | -33174.4% | · | · | |
| EBITDA Margin | -18069.6% | -2637.4% | -2362.6% | -8477.4% | -33478.8% | · | · | |
| ROA | -151.2% | -77.5% | -68.8% | -63.1% | -35.2% | -30.5% | · | |
| ROE | -167.0% | -116.6% | -110.0% | -91.6% | -41.9% | -94.5% | · | |
| ROIC | -87.8% | -140.9% | -123.4% | -99.1% | -44.5% | 20.3% | · |
Liquidez e Solvência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.0 | 14.1 | 6.3 | 5.8 | 24.2 | 30.4 | · | |
| Quick Ratio | 12.8 | 11.8 | 5.7 | 5.4 | 22.0 | 29.4 | · |
Eficiência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
Por Ação
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $150.49 | $12.02 | $1.19 | $2.41 | $4.64 | $6.55 | · | |
| Revenue / Share | $0.86 | $0.73 | $0.06 | $0.03 | · | · | · | |
| Cash Flow / Share | $-4.93 | $-16.09 | $-1.39 | $-1.69 | · | · | · | |
| Cash / Share | $161.29 | $10.76 | $0.79 | $1.28 | $2.48 | $6.48 | · | |
| Dividend / Share | $0.00 | $0.00 | · | · | $0.00 | $0.00 | · | |
| Dividend Paid / Share | · | · | · | · | $0.00 | $0.00 | · | |
| EPS (TTM) | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 | · | · |
Taxas de Crescimento
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 38.3% | -50.0% | 133.9% | 362.8% | · | · | · | |
| Revenue CAGR 3Y | 17.4% | 75.5% | · | · | · | · | · |
Avaliação (TTM)
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1M | $844.0K | $2M | $722.0K | $156.0K | · | · | |
| Net Income TTM | $-210M | $-21M | $-38M | $-62M | $-52M | $-35M | · |
Demonstração de Resultados
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $26M | $24M | $23M | $1M | $1M | $678.0K | $1M | $1M | $2M | $2M | $3M | $3M | $8M | $10M | $11M | $10M | |
| SG&A Expense | $9M | $7M | $4M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Operating Expenses | $35M | $31M | $202M | $3M | $3M | $3M | $7M | $4M | $6M | $6M | $7M | $9M | $11M | $13M | $14M | $14M | |
| Operating Income | $-35M | $-31M | $-202M | $-3M | $-3M | $-3M | $-7M | $-4M | $-6M | $-6M | $-7M | $-9M | $-11M | $-13M | $-14M | $-14M | |
| Other Non-op | $4M | $3M | $1M | $23.0K | $-12.0K | $68.0K | $353.0K | $-36.0K | $281.0K | $264.0K | $196.0K | $447.0K | $415.0K | $498.0K | $-544.0K | $-108.0K | |
| Pretax Income | $-31M | $-28M | $-201M | $-3M | $-3M | $-3M | $-7M | $-4M | $-5M | $-5M | $-6M | $-8M | $-11M | · | · | · | |
| Income Tax | $255.0K | $42.0K | $44.0K | $0 | $4.0K | $2.0K | $-8.0K | $7.0K | $42.0K | · | · | · | · | · | · | · | |
| Net Income | $-31M | $-28M | $-201M | $-3M | $-3M | $-3M | $-7M | $-4M | $-5M | $-5M | $-6M | $-8M | $-11M | $-13M | $-14M | $-14M | |
| EPS (Basic) | $-0.39 | $-0.62 | $10.86 | $-2.36 | $-2.60 | $-1.92 | $-5.17 | $-3.39 | $-4.92 | $-5.05 | $-27.66 | $-7.50 | $-0.41 | $-0.51 | $-0.55 | $-0.54 | |
| EPS (Diluted) | $-0.39 | $-0.62 | $10.86 | $-2.36 | $-2.60 | $-1.92 | $-5.17 | $-3.39 | $-4.92 | $-5.05 | $-27.66 | $-7.50 | $-0.41 | $-0.51 | $-0.55 | $-0.54 | |
| Shares (Basic) | 61,117,057 | 34,299,182 | · | 1,327,039 | 1,322,553 | 1,322,011 | · | 1,144,978 | 1,084,622 | 1,084,509 | · | 1,084,191 | 26,375,076 | 25,672,902 | · | 25,491,786 | |
| Shares (Diluted) | 61,117,057 | 34,299,182 | · | 1,327,039 | 1,322,553 | 1,322,011 | · | 1,144,978 | 1,084,622 | 1,084,509 | · | 1,084,191 | 26,375,076 | 25,672,902 | · | 25,491,786 | |
| EBITDA | $-35M | $-31M | · | $-3M | $-3M | $-3M | · | $-4M | $-6M | $-6M | · | $-9M | $-11M | $-13M | · | $-14M |
Balanço Patrimonial
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $541M | $533M | $258M | $8M | $10M | $12M | $14M | $20M | $23M | $21M | $21M | $23M | $23M | $25M | $33M | $28M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | $6M | $12M | $21M | $29M | $28M | $27M | $41M | |
| Prepaid Expense | $3M | $3M | $3M | $2M | $3M | $3M | $3M | $2M | $2M | $3M | $4M | $3M | $3M | $4M | $4M | $2M | |
| Current Assets | $544M | $535M | $260M | $10M | $13M | $15M | $17M | $21M | $25M | $31M | $37M | $47M | $55M | $57M | $64M | $71M | |
| PP&E (Net) | · | · | $36.0K | $41.0K | $47.0K | $52.0K | $57.0K | $62.0K | $67.0K | $73.0K | $78.0K | $125.0K | $328.0K | $345.0K | $357.0K | $338.0K | |
| PP&E (Gross) | · | · | $108.0K | $108.0K | $108.0K | $107.0K | $107.0K | $107.0K | $106.0K | $107.0K | $107.0K | $430.0K | $425.0K | $425.0K | $419.0K | $379.0K | |
| Accum. Depreciation | · | · | $72.0K | $67.0K | $61.0K | $55.0K | $50.0K | $45.0K | $39.0K | $34.0K | $29.0K | $305.0K | $97.0K | $80.0K | $62.0K | $41.0K | |
| Other Non-current Assets | $48.0K | $34.0K | $0 | $837.0K | $542.0K | $317.0K | $163.0K | $2M | $2M | $2M | $1M | $2M | $2M | $2M | $2M | $3M | |
| Total Assets | $544M | $535M | $261M | $11M | $14M | $15M | $17M | $23M | $27M | $32M | $38M | $50M | $59M | $65M | $73M | $82M | |
| Accounts Payable | $3M | $819.0K | $444.0K | $520.0K | $756.0K | $354.0K | $377.0K | $503.0K | $724.0K | $2M | $2M | $4M | $6M | $4M | $3M | $2M | |
| Accrued Liabilities | $9M | $6M | $2M | $2M | $2M | $1M | $820.0K | $2M | $3M | $3M | $4M | $8M | $9M | $11M | $8M | $7M | |
| Current Liabilities | $28M | $24M | $20M | $3M | $3M | $2M | $1M | $2M | $4M | $4M | $6M | $13M | $15M | $14M | $11M | $9M | |
| Capital Leases | · | · | $53.0K | $57.0K | $60.0K | $60.0K | $61.0K | · | · | · | $66.0K | $112.0K | $206.0K | $234.0K | $328.0K | $440.0K | |
| Other Non-current Liabilities | $27.0K | $27.0K | $28.0K | $49.0K | $49.0K | $45.0K | $43.0K | · | · | · | · | · | · | · | · | · | |
| Total Liabilities | $28M | $24M | $20M | $3M | $3M | $2M | $1M | $2M | $4M | $4M | $6M | $13M | $15M | $14M | $11M | $9M | |
| Common Stock | $1.0K | $1.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Paid-in Capital | $932M | $894M | $311M | $292M | $292M | $292M | $292M | $291M | $290M | $289M | $288M | $287M | $285M | $281M | $280M | $278M | |
| Retained Earnings | $-546M | $-515M | $-487M | $-287M | $-283M | $-280M | $-278M | $-271M | $-267M | $-262M | $-256M | $-250M | $-241M | $-231M | $-218M | $-204M | |
| AOCI | $732.0K | $754.0K | $802.0K | $823.0K | $809.0K | $300.0K | $97.0K | $665.0K | $197.0K | $326.0K | $380.0K | $46.0K | $-137.0K | $-127.0K | $-244.0K | $-2M | |
| Stockholders' Equity | $516M | $512M | $240M | $8M | $11M | $14M | $16M | $21M | $24M | $28M | $32M | $37M | $44M | $50M | $62M | $73M | |
| Liabilities + Equity | $544M | $535M | $261M | $11M | $14M | $15M | $17M | $23M | $27M | $32M | $38M | $50M | $59M | $65M | $73M | $82M | |
| Shares Outstanding | 61,734,601 | 60,303,212 | 1,597,321 | 1,327,212 | 1,324,560 | 1,322,359 | 1,316,989 | 1,253,843 | 27,121,030 | 27,112,697 | 1,084,509 | 27,112,697 | 27,021,899 | 25,673,474 | 25,652,392 | 25,581,029 |
Fluxo de Caixa
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $6M | $3M | $483.0K | $164.0K | $172.0K | $179.0K | $308.0K | $681.0K | $891.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | |
| Restructuring | · | · | · | · | · | · | $0 | $0 | $-2M | $3M | · | $3M | · | · | · | · | |
| Operating Cash Flow | $-22M | $-21M | $566.0K | $-3M | $-2M | $-2M | $-5M | $-4M | $-4M | $-6M | $-11M | $-8M | $-8M | $-9M | $-11M | $-10M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $41.0K | $138.0K | |
| Investing Cash Flow | · | · | · | · | · | · | $0 | $0 | $6M | $6M | $10M | $8M | $3M | $1M | $14M | $8M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | $171.0K | $3M | $23.0K | $65.0K | $424.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $23.0K | · | · | |
| Financing Cash Flow | $30M | $296M | · | · | · | · | · | · | · | · | $0 | $171.0K | $3M | $23.0K | $65.0K | $424.0K | |
| Taxes Paid | · | · | $0 | $0 | $3.0K | $2.0K | · | · | · | · | · | · | · | · | · | · |
Lucratividade
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -862.1% | -1003.6% | · | -7514.3% | -6842.0% | -3512.2% | · | -2630.1% | -2618.3% | -2233.8% | · | -1814.6% | -2524.7% | -3108.8% | · | -6163.8% | |
| Net Margin | -768.0% | -905.0% | · | -7459.5% | -6874.0% | -3423.0% | · | -2659.6% | -2506.1% | -2131.1% | · | -1720.1% | -2430.8% | -2994.0% | · | -6212.7% | |
| Pretax Margin | -761.7% | -903.6% | · | -7459.5% | -6866.0% | -3420.3% | · | -2654.8% | -2486.4% | · | · | · | · | · | · | · | |
| EBITDA Margin | -862.1% | -1003.6% | · | -7514.3% | -6842.0% | -3512.2% | · | -2630.1% | -2618.3% | -2233.8% | · | -1814.6% | -2524.7% | -3108.8% | · | -6163.8% | |
| ROA | -11.2% | -10.1% | · | -18.4% | -16.8% | -10.6% | · | -10.6% | -12.4% | -11.3% | · | -12.3% | -14.2% | -15.0% | · | -12.6% | |
| ROE | -11.8% | -10.6% | · | -21.6% | -19.9% | -12.1% | · | -13.3% | -15.9% | -14.0% | · | -14.8% | -16.7% | -17.1% | · | -13.6% | |
| ROIC | -6.8% | -6.0% | · | -39.4% | -31.3% | -19.0% | · | -18.4% | -23.8% | · | · | · | · | · | · | · |
Liquidez e Solvência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 19.7 | 22.5 | · | 3.7 | 5.0 | 9.6 | · | 8.7 | 6.8 | 7.1 | · | 3.7 | 3.7 | 4.1 | · | 8.0 | |
| Quick Ratio | 19.6 | 22.4 | · | 2.9 | 3.9 | 7.7 | · | 8.1 | 6.2 | 6.3 | · | 3.5 | 3.5 | 3.8 | · | 7.8 |
Eficiência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Por Ação
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $8.36 | $8.48 | · | $6.03 | $8.27 | $10.37 | · | $16.70 | $0.87 | $1.04 | · | $1.38 | $1.62 | $1.96 | · | $2.84 | |
| Revenue / Share | $0.07 | $0.09 | · | $0.03 | $0.04 | $0.06 | · | $0.13 | $0.01 | $0.01 | · | $0.02 | $0.02 | $0.02 | · | $0.01 | |
| Cash Flow / Share | · | $-0.60 | · | · | · | $-1.84 | · | · | · | $-0.22 | · | · | · | $-0.36 | · | · | |
| Cash / Share | $8.76 | $8.84 | · | $5.73 | $7.71 | $9.03 | · | $15.69 | $0.84 | $0.78 | · | $0.85 | $0.85 | $0.98 | · | $1.11 | |
| Dividend / Share | $0.00 | $0.00 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $7.49 | $5.28 | · | $-12.05 | $-13.08 | $-15.40 | · | $-41.02 | $-45.13 | $-40.62 | · | $-8.97 | $-2.01 | $-2.27 | · | $-2.41 |
Avaliação (TTM)
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $4M | · | $394.0K | $498.0K | $661.0K | · | $956.0K | $1M | $2M | · | $2M | $1M | $1M | · | $468.0K | |
| Net Income TTM | $-263M | $-235M | · | $-16M | $-17M | $-18M | · | $-21M | $-25M | $-31M | · | $-46M | $-52M | $-58M | · | $-61M | |
| Market Cap | $1.61B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 3.5 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/S | 196.5 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 3.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 3.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 28.8% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Período mais recente à esquerda · valores nulos mostrados como ·
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Margem Operacional % | -18069.6% | -2637.4% | -2362.6% | -8477.4% | -33478.8% |
| Lucro líquido | $-210M | $-21M | $-38M | $-62M | $-52M |
| EPS Diluído | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 13.0 | 14.1 | 6.3 | 5.8 | 24.2 |
| Índice de Liquidez Seca | 12.8 | 11.8 | 5.7 | 5.4 | 22.0 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fluxo de caixa livre | · | · | · | $-43M | $-53M |
Ativistas e proprietários de 5%+ 3 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest V L.P., Peter Evan Harwin, Tomas Kiselak ×2 declarações | 11 de Fevereiro de 2026 | 19,99% | Emenda | · | SEC |
| Novo Holdings A/S ×6 declarações | 9 de Outubro de 2025 | 0,00% | Emenda | · | SEC |
| OrbiMed Advisors LLC, OrbiMed Advisors Israel II Limited, OrbiMed Israel GP II, L.P., OrbiMed Capital GP VII LLC, OrbiMed Genesis GP LLC, OrbiMed Capital LLC ×7 declarações | 18 de Setembro de 2023 | · | Declaração inicial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Executivos da empresa 25 insiders · 11 diretores · 14 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Jennifer Jarrett | Director, President and CEO | 25 de Setembro de 2026 P | 512.500 | 1 | 0 | $252.875 |
| Hans T. Schambye | Chief Executive Officer | 2 de Janeiro de 2026 M | 4.682 | 0 | 1 | $-14.966 |
| Lori Firmani | Chief Financial Officer | 2 de Janeiro de 2026 M | 931 | 0 | 1 | $-2.890 |
| Jonathan Freve | Chief Financial Officer | 3 de Janeiro de 2024 A | 12.000 | 0 | 0 | $0 |
| Sherwin Sattarzadeh | Chief Operating Officer | 5 de Janeiro de 2026 A | 190.376 | 0 | 0 | $0 |
| Anders Pedersen | Chief Operating Officer | 4 de Janeiro de 2023 A | 3.746 | 0 | 0 | $0 |
| Garrett Winslow | General Counsel | 3 de Julho de 2026 M | 2.289 | 0 | 2 | $-12.797 |
| Becker L. Hewes | Chief Medical Officer | 5 de Janeiro de 2026 A | 264.629 | 0 | 0 | $0 |
| Matthew Kronmiller | EVP Strategy and CBO | 3 de Janeiro de 2025 A | · | 0 | 0 | $0 |
| Stephanie Oestreich | Chief Business Officer | 4 de Janeiro de 2023 A | · | 0 | 0 | $0 |
| Bertil Lindmark | Chief Medical Officer | 4 de Janeiro de 2023 A | 16.604 | 0 | 0 | $0 |
| Julianne Bruno | Conselheiro | 23 de Março de 2026 A | 137.032 | 0 | 0 | $0 |
| Christopher W. Cain | Conselheiro | 23 de Março de 2026 A | · | 0 | 0 | $0 |
| Cameron Turtle | Conselheiro | 23 de Março de 2026 A | · | 0 | 0 | $0 |
| Michael Landsittel | Conselheiro | 23 de Março de 2026 A | · | 0 | 0 | $0 |
| Anne Prener | Conselheiro | 18 de Junho de 2025 A | · | 0 | 0 | $0 |
| Amy B Wechsler | Conselheiro | 18 de Junho de 2025 A | · | 0 | 0 | $0 |
| Jayson Donald Alexander Dallas | Conselheiro | 18 de Junho de 2025 A | · | 0 | 0 | $0 |
| Amit Munshi | Conselheiro | 18 de Junho de 2025 A | 4.793 | 0 | 0 | $0 |
| David Shapiro | Conselheiro | 18 de Junho de 2025 A | · | 0 | 0 | $0 |
| Carl Goldfischer | Conselheiro | 18 de Junho de 2025 A | 19.432 | 0 | 0 | $0 |
| Chau Quang Khuong | Conselheiro | 14 de Junho de 2023 A | 1.031.811 | 0 | 0 | $0 |
| Stephan Christgau | Conselheiro | 2 de Novembro de 2020 C | 546.136 | 0 | 0 | $0 |
| Novo Holdings A/S | Detentor de 10% | 2 de Novembro de 2020 C | 2.497.791 | 0 | 0 | $0 |
| Andrew Cheng | · | 12 de Agosto de 2026 A | · | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 12 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| IWO · iShares Trust | 0,06% | 344.459 SH | 11 de Setembro de 2026 | Diário |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,06% | 39.408 SH | 19 de Agosto de 2026 | Diário |
| IWM · iShares Trust | 0,05% | 1.358.452 SH | 11 de Setembro de 2026 | Diário |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,04% | 307.241 SH | 19 de Agosto de 2026 | Diário |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 14.454 SH | 19 de Agosto de 2026 | Diário |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,02% | 2.743 SH | 2 de Outubro de 2026 | Diário |
| WSML · iShares Trust | 0,01% | 2.560 SH | 11 de Setembro de 2026 | Diário |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 212.600 SH | 19 de Agosto de 2026 | Diário |
| IWV · iShares Trust | 0,00% | 14.297 SH | 11 de Setembro de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 4.396 SH | 19 de Agosto de 2026 | Diário |
| IWN · iShares Trust | · | 153.406 SH | 11 de Setembro de 2026 | Diário |
| ISCB · iShares Trust | · | 2.013 SH | 11 de Setembro de 2026 | Diário |
DMRA Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
classificação · 16 analistas
COMPRA
Alvo mediano
$45.00
+117,9%
6 37,5%
Compra forte
9 56,2%
Compra
1 6,2%
Manter
0 0,0%
Venda
0 0,0%
Venda forte
Preço-alvo de 12 meses
9 analistas · 2026-09-28Alvo médio $46.89 +127,1%
← Abaixo de todos os alvos
Preço atual $20.65
Mín$40.00
Média$46.89
Máx$60.00
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| DMRA | · | · | 38.3% | -17981.1% | -167.0% | · |
| KLRA | · | · | · | · | · | · |
| ORIC | $806M | -5.6 | · | · | -36.5% | · |
| REPL | $633M | -2.3 | · | · | -146.2% | · |
| MNKD | $1.75B | 283.5 | 22.2% | 1.7% | -11.1% | · |
| BCAX | $953M | -6.7 | · | · | -33.0% | · |
| TRAX | · | · | · | · | · | · |
| VOR | $506M | -0.2 | · | · | 83.4% | · |
| MGTX | $645M | -5.6 | 144.6% | -140.3% | 8062.2% | · |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Fonte: SEC 10-Q arquivado Ago 10, 2026